Drugs / Oxybutynin
Oxybutynin
also known as
Oxybutynin chloride · DITROPAN XL · Oxytrol · Ditropan · 5058 · Anturol; Oxybutynin Gel 3% · BAY839380 · Contimin 2.5 · +28 more
Small molecule targets CHRM2, CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DITROPAN XL | — | 2004-06-30 | fda.gov ↗ |
| Approved | EU (EMA) | Kentera (previously Oxybutynin Nicobrand) | — | 2004-06-15 | europa.eu ↗ |
| Label expansion | US (FDA) | DITROPAN | — | 2003-04-15 | fda.gov ↗ |
| Approved | US (FDA) | DITROPAN | — | 1975-07-16 | fda.gov ↗ |
Trials 58 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03205605 | Jan 2018 → Nov 2019 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT00926926 | Jun → Jul 2009 | — | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00752141 | Sep → Oct 2008 | — | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00501267 | Jun → Aug 2007 | overactive bladder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00649272 | Jan 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650481 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648843 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649129 | Jul → Aug 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649727 | Jul 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07577661 | Jun 2026 → Dec 2027 expected | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05944965 | Dec 2023 → Jun 2025 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT05550246 | May 2022 → Dec 2024 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07391878 | Feb 2026 → Dec 2027 expected | overactive bladder | Trigone Pharma Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05933603 | Sep 2023 → Jun 2026 overdue | Down syndrome, obstructive sleep apnea syndrome | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05102396 | Sep 2022 → Jun 2024 | isolated hyperchlorhidrosis, sweat gland disorder | Samantha Rodrigues Camargo Neves de Moura | Unknown | No outcome recorded |
| Phase 2 | NCT04600336 | Oct 2021 → Feb 2024 | prostate carcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT04526353 | Sep 2020 → Feb 2028 expected | male reproductive system disorder | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase 2 | NCT04445688 | Jul → Dec 2020 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
| Phase 2 | NCT04449133 | Jul → Oct 2020 | obstructive sleep apnea syndrome | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 2 | NCT03919955 | Sep 2019 → Sep 2023 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03845023 | Mar → Oct 2019 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
| Phase 2 | NCT02240459 | Aug 2016 → Jan 2020 | cognitive impairment with or without cerebellar ataxia, overactive bladder | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT01370811 | Aug 2011 → Sep 2012 | — | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00816972 | Apr → Jun 2005 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT00990886 | Apr 2004 → Jan 2005 | — | Ortho-McNeil Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04394143 | Oct 2020 → Jul 2021 | obstructive sleep apnea syndrome | Raphael Heinzer | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT07027020 | Jan 2026 → Jan 2028 expected | spina bifida | Central Hospital, Nancy, France | Recruiting | No outcome recorded |
| Phase 3 | NCT06106529 | Oct 2024 → Jan 2029 expected | female breast carcinoma | Reinier de Graaf Groep | Recruiting | No outcome recorded |
| Phase 3 | NCT03952299 | Sep 2021 → Dec 2026 expected | overactive bladder | University of California, Davis | Recruiting | No outcome recorded |
| Phase 3 | NCT02961790 | Dec 2016 → Apr 2018 | ductal breast carcinoma in situ, lobular breast carcinoma in situ | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 3 | NCT01050114 | Aug 2013 → Jul 2018 | overactive bladder | Christopher Patrick Smith | Unknown | No outcome recorded |
| Phase 3 | NCT01855256 | Jun 2013 → Feb 2014 | isolated hyperchlorhidrosis | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT04534491 | May 2010 → Jun 2011 | overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00909181 | Mar 2009 → Jul 2010 | overactive bladder | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00350636 | Jun 2006 → May 2007 | overactive bladder | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00338624 | May 2004 → Jun 2005 | urinary system disorder | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00269724 | Mar → Sep 1997 | overactive bladder | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00269750 | Jul 1996 → Feb 1997 | urinary bladder disorder | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00304499 | Dec 1995 → Dec 1996 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00293839 | ? → Dec 2002 | overactive bladder | Alza Corporation | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07280468 | Mar 2026 → Jan 2030 expected | Down syndrome, obstructive sleep apnea syndrome | University of Arizona | Recruiting | No outcome recorded |
| Phase 4 | NCT06295562 | Nov 2024 → Oct 2025 | obstructive sleep apnea syndrome | China Medical University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04090190 | Oct 2019 → May 2021 | overactive bladder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01824420 | Mar 2013 → Feb 2017 | overactive bladder | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01192568 | May 2011 → Aug 2023 | overactive bladder | AbbVie | Completed | No outcome recorded |
| Phase 4 | NCT01310712 | Dec 2010 → Feb 2011 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01796548 | Dec 2008 → Dec 2010 | overactive bladder | Janssen-Cilag Ltd.,Thailand | Terminated | No outcome recorded |
| Phase 4 | NCT03877289 | Oct 2008 → Jul 2014 | cystitis | University of Calgary | Completed | No outcome recorded |
| Phase 4 | NCT00613327 | Sep 2007 → Jun 2008 | overactive bladder | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00411437 | Dec 2006 → Jun 2007 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00224029 | Dec 2004 → Dec 2005 | overactive bladder | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00224146 | May 2004 → May 2005 | overactive bladder | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06966778 | Sep 2025 → Dec 2028 expected | cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| — | NCT02704013 | Apr 2016 → Dec 2017 | overactive bladder | Children's Hospital Zagreb | Unknown | No outcome recorded |
| — | NCT02633371 | Feb → Jun 2016 | isolated hyperchlorhidrosis | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02973659 | May 2015 → Aug 2016 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT00892450 | May 2009 → Sep 2014 | Parkinson disease, overactive bladder | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT01118429 | Jan 2007 → Jun 2009 | extraoral halitosis due to methanethiol oxidase deficiency, isolated hyperchlorhidrosis | Grupo de Cirurgia Vascular | Completed | No outcome recorded |
Also used as a comparator or background therapy in 40 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06162065 Background | Nov 2023 → Jan 2024 | overactive bladder | Universidad de Valparaiso | Unknown | No outcome recorded |
| Phase 1 | NCT00649259 Comparator | Oct → Nov 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03720353 Comparator | Dec 2018 → Dec 2019 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02908529 Comparator | Sep 2016 → Dec 2017 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06181591 Comparator | Apr 2024 → Apr 2025 | overactive bladder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04115878 Comparator | Oct 2020 → Dec 2022 | Down syndrome, obstructive sleep apnea syndrome | University of Arizona | Completed | No outcome recorded |
| Phase 2 | NCT01328015 Comparator | Mar → May 2010 | isolated hyperchlorhidrosis | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT00749632 Comparator | Jul 2007 → Oct 2008 | overactive bladder | FemmePharma Global Healthcare, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00170768 Comparator | Feb → May 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07114640 Comparator | Aug 2025 → Dec 2028 expected | overactive bladder | Far Eastern Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06737016 Background | Nov 2024 → May 2026 overdue | posterior urethral valve | Mansoura University | Recruiting | No outcome recorded |
| Phase 3 | NCT05658874 Background | Dec 2022 → Dec 2024 | interstitial cystitis, levator syndrome | Jocelyn Fitzgerald | Terminated | No outcome recorded |
| Phase 3 | NCT05637671 Comparator | Feb 2022 → Dec 2023 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02099695 Comparator | Dec 2015 → Jan 2016 | isolated hyperchlorhidrosis | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03050827 Comparator | May 2014 → Aug 2017 | diabetic polyneuropathy | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 3 | NCT02538302 Comparator | Jul 2013 → Jul 2015 | nocturnal enuresis | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01557244 Comparator | Jul 2012 → Nov 2019 | urinary bladder disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01716624 Comparator | May 2011 → Mar 2012 | low compliance bladder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT01187498 Comparator | Jan 2005 → Oct 2009 | overactive bladder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07679282 Comparator | Sep 2026 → Mar 2030 expected | obstructive sleep apnea syndrome | Sairam Parthasarathy | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04909255 Comparator | Mar 2021 → Aug 2022 | Sjogren syndrome, overactive bladder | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02176642 Comparator | Aug 2014 → Nov 2016 | urinary bladder disorder | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT01423838 Comparator | Sep 2011 → Sep 2012 | overactive bladder | Adana Numune Training and Research Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01178827 Comparator | Aug 2010 → Mar 2011 | overactive bladder | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01126424 Comparator | Apr → Dec 2010 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00629642 Comparator | Mar 2008 → Jan 2011 | multiple sclerosis, spinal cord disorder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00800462 Comparator | Mar 2008 → Jun 2012 | overactive bladder, spinal cord injury | Toronto Rehabilitation Institute | Completed | No outcome recorded |
| Phase 4 | NCT00547378 Comparator | Oct 2007 → Aug 2016 | overactive bladder | MedtronicNeuro | Completed | No outcome recorded |
| Phase 4 | NCT01899794 Comparator | Oct 2007 → Apr 2013 | female stress incontinence | Jewish General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00431041 Comparator | Dec 2006 → Feb 2008 | overactive bladder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00224016 Comparator | Dec 2004 → Apr 2007 | urinary bladder disorder | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07259148 Comparator | Nov 2025 → Jan 2026 overdue | overactive bladder | Emilio José Dávila Álvarez | Active not recruiting | No outcome recorded |
| — | NCT07668232 Comparator | Jan → Dec 2025 | posterior urethral valve | South Valley University | Completed | No outcome recorded |
| — | NCT05100017 Comparator | Sep 2021 → Jun 2025 overdue | nephrolithiasis, ureterolithiasis | Northwestern University | Active not recruiting | No outcome recorded |
| — | NCT07081906 Comparator | Feb → Jul 2019 | overactive bladder | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Completed | No outcome recorded |
| — | NCT02483793 Comparator | Jul 2015 → Dec 2016 | urinary system disorder | Phoenix Children's Hospital | Withdrawn | No outcome recorded |
| — | NCT01829425 Comparator | Apr 2013 → Oct 2017 | urinary bladder disorder | University of New Mexico | Completed | No outcome recorded |
| — | NCT01477736 Comparator | Jan 2009 → Nov 2010 | spinal cord injury | Centro de Reabilitação e Readaptação Dr. Henrique Santillo | Completed | No outcome recorded |
| — | NCT00223821 Background | Sep 2003 → Nov 2008 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
Evidence & citations 42 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxybutynin | “adults with loud habitual snoring took atomoxetine plus oxybutynin for 10 days before bedtime at full adult doses (80 and 5 mg, respectively; half-dose run-in on days 1-3) and...” PMID 40471069 ↗ Sep 202593“Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.” PMID 36861433 ↗ Jul 2023 “This study evaluated the efficacy and safety of AD036 (atomoxetine 80 mg and oxybutynin 5 mg) in the treatment of OSA.” PMID 35551600 ↗ May 2022 “Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg” NCT00547378 ↗ “TRG-200 KIT, a novel intravesical sustained-release delivery system containing oxybutynin.” NCT07391878 ↗ “comparing 4 mg reboxetine plus 5 mg oxybutynin (Reb-Oxy) vs placebo in patients with OSA.” PMID 34543665 ↗ Sep 2021 “Oxybutynin is primarily indicated for the treatment of overactive bladder syndrome.” NCT07668232 ↗ “Overactive Bladder Medication( Trospium/Oxybutynin/Detrol vs. Mirabegron)” NCT05658874 ↗ “0.5 mg/kg (max 40 mg) of atomoxetine and 5mg oxybutynin taken nightly.” NCT07280468 ↗ “Oxybutynin (Ditropan Extended Release or equivalent generic)” NCT01829425 ↗ “flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel)” NCT01796548 ↗ “* Oxybutynin” NCT07016451 ↗ “Oxybutynin” NCT00350636 ↗ |
| Known as | 5058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Anturol; Oxybutynin Gel 3% | “Anturol; Oxybutynin Gel 3%” NCT00909181 ↗ |
| Known as | BAY839380 | “Oxybutynin (Oxytrol, BAY839380)” NCT04534491 ↗ |
| Known as | Contimin 2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Contimin 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Cystrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Ditropan | “The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge...” NCT00269750 ↗1“Oxybutynin (Ditropan) ER 5mg QD” NCT01824420 ↗ |
| Known as | DITROPAN XL | “The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets...” NCT00649129 ↗2“A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride)...” NCT00338624 ↗ “Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder” NCT00293839 ↗ |
| Known as | Gelnique | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Kentera | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Kentera (previously oxybutynin nicobrand) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Lyrinel xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | MJ 4309-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | NSC-759108 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | OROS oxybutynin | “The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge...” NCT00269750 ↗ |
| Known as | Oxibutinina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | OXY-ER | “flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel)” NCT01796548 ↗ |
| Known as | OXY-TDS | “oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA)” PMID 17187655 ↗ Dec 2006 |
| Known as | Oxybutynin (Ditropan Extended Release or equivalent generic) | “Oxybutynin (Ditropan Extended Release or equivalent generic)” NCT01829425 ↗ |
| Known as | Oxybutynin chloride | “OROS® (oxybutynin chloride) 5 mg tablets, one to six tablets per day (5 mg/day to 30 mg/day) as a single morning oral dose for 11 days up to 70 days, and Ditropan (oxybutynin...” NCT00269750 ↗17“This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin...” NCT00800462 ↗ “A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride)...” NCT00338624 ↗ “Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.” NCT06181591 ↗ “Transdermally administered oxybutynin chloride topical gel 10% (OTG) has a low propensity for anticholinergic adverse effects” PMID 22909146 ↗ Oct 2012 “Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg” NCT00648843 ↗ “10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.” NCT01192568 ↗ “Individually-titrated, extended-release oxybutynin chloride with management of side-effects.” NCT00223821 ↗ “Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally” NCT01796548 ↗ “Oxybutynin Chloride Extended-release Tablets 5 mg” NCT00650481 ↗ “Oxybutynin chloride 15 mg once daily for 12 weeks” NCT00990886 ↗ “Oxybutynin Chloride ER Tablets 10 mg” NCT00649727 ↗ “Oxybutynin Chloride ER Tablets 10 mg” NCT00649129 ↗ “Drug: Oxybutynin Chloride” NCT04600336 ↗ |
| Known as | Oxybutynin Cl | “Drug: Oxybutynin Cl” NCT00800462 ↗ |
| Known as | oxybutynin ER | “One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.” NCT05637671 ↗ |
| Known as | Oxybutynin Hydrochloride | “Drug: Oxybutynin Hydrochloride” NCT07027020 ↗ |
| Known as | oxybutynin IR | “oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days” NCT01178827 ↗ |
| Known as | oxybutynin transdermal delivery system | “oxybutynin transdermal delivery system (Oxytrol(r))” NCT00224146 ↗ |
| Known as | oxybutynin transdermal system | “oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA)” PMID 17187655 ↗ Dec 2006 |
| Known as | oxybutynin-TDS | “oxybutynin transdermal system (oxybutynin-TDS) in spinal cord injury patients with neurogenic detrusor overactivity and incontinence” PMID 19628264 ↗ Jul 2009 |
| Known as | Oxybutynine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Oxytrol | “oxybutynin transdermal delivery system (Oxytrol(r))” NCT00224146 ↗ |
| Known as | Oxytrol for women | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Oxytrol(r) | “oxybutynin transdermal delivery system (Oxytrol(r))” NCT00224146 ↗ |
| Known as | PMS-Oxybutynin | “The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.).” NCT04526353 ↗ |
| Known as | Pollakisu | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Promictuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Tropax | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Urimin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Action | Inhibit | “Oxybutynin is a parasympatholytics with relaxant effect on bladder detrusor muscle by action on muscarinic antagonist.” NCT01328015 ↗2“Muscarinic acetylcholine receptor M2 antagonist” CHEMBL1231 ↗ “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1231 ↗ |
| Modality | Small molecule | — CHEMBL1231 ↗ |
| Route | Other | “1.3, 2.6, 3.9 mg/day transdermal” NCT00224016 ↗ |
| Target | CHRM2 | “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL1231 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1231 ↗ |